Free press releases distribution network?

Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Pfizer Writes Off of $2.8bn Exubera Hits Inhalable Insulin Market Says Report - Report Buyer, the online destination for business intelligence for major industry sectors, has now added a new report showing that Pfizer has abandoned inhaled insulin product Exubera, resulting in a $2.8 billion write-off
Pfizer Writes Off of $2.8bn Exubera Hits Inhalable Insulin Market Says Report

 

PRZOOM - /newswire/ - London, United Kingdom, 2007/10/31 - Report Buyer, the online destination for business intelligence for major industry sectors, has now added a new report showing that Pfizer has abandoned inhaled insulin product Exubera, resulting in a $2.8 billion write-off.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“Pipeline Insight: Insulins - Inhalable insulins unlikely to become blockbusters?” reports that overall
quarterly revenue for Pfizer fell 2.4 percent to $12 billion, and third-quarter net income dropped 77%. Pfizer also stands to lose patent protection within the next four years on drugs accounting for about half of its 2006 revenue. Key among these products is cholesterol drug Atorvastatin® (Lipitor), the world’s single most successful drug. The discontinuation of Exubera leaves Pfizer with one less drug to make up for those losses. While Pfizer will live to fight another day, the same cannot now be said for Exubera.

Obviously expecting big (and profitable) things, Pfizer paid $1.3 billion to Paris-based Sanofi-Aventis in 2006 for the rights to Exubera and insulin production plants in Germany. The product had only $4 million in worldwide sales in the second quarter, a disappointing result, the company said. Pfizer began airing television advertisements in recent months in an unsuccessful last-ditch attempt to stimulate demand and establish a foothold in the market.

Once touted as the next big thing in the treatment of diabetes, Exubera was forecast to be a blockbuster by most analysts. However, after separating the hype from the reality, authors of the report quickly recognised that a number of issues plagued the inhaled insulin class and thus restricted its commercial potential.

The proposed convenience advantage, and any concomitant benefit in compliance, of Exubera was negated by the fact that it was only available with a cumbersome and unwieldy delivery device. Furthermore, despite extensive clinical trials, the risks of long-term lung damage and carcinogenicity remained unquantified. New classes of antidiabetic agents, namely GLP-1 agonists (Byetta) and DPP4 inhibitors (Januvia) are also vying for market share, significantly restricting the size of the portion of market that would be available to Exubera.

Finally, the fact that Exubera was in essence a repackaged form of insulin, only offering a suggested convenience advantage rather than being a truly novel treatment made it unappealing to healthcare providers, who viewed the unmet need for inhaled insulin as non-existent and thus either refused to recommend it (UK and Germany) or offered reimbursement at a higher tier than most injected insulin (US).

The withdrawal of Exubera will force the developers of second generation inhaled insulins –namely Novo Nordisk, Eli Lilly and Mannkind – to assess whether the continuation of their projects is a viable decision. It has now become clear that true convenience in the form of a discreet portable device is required in order to win over patients, and a true therapeutic advantage compared to traditionally administered insulin needs to be proven to secure reimbursement.

“Pipeline Insight: Insulins - Inhalable insulins unlikely to become blockbusters?” is available from Report Buyer. For more information visit the website.

Report Buyer product ID: DAT04261

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Pfizer Writes Off of $2.8bn Exubera Hits Inhalable Insulin Market Says Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Jonna Dagliden 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Report Buyer Ltd / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Sparta Systems Broadens Partnership with TrackWise Implementation Specialist Equality Systems
Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016
Agfa and LCsys Team Up to Launch ABSOLUT-ID, Their Turnkey Integrated Solution for the Production of High Security ID Cards
ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference
AccuVein to Exhibit Leading Vein Visualization Technology at American Society for Dermatologic Surgery Annual Meeting
US Biomedical Textiles Transform Implant Device Technology by Aligning to Changes in Patient Preference Finds Frost & Sullivan
Frost & Sullivan Commends Influence Health for Constantly Evolving its Patient Engagement Products to Accelerate Market Transformation
Frost & Sullivan Awards Carestream Top Honors for OnSight 3D Extremity System
Sparta Systems Launches the Next-Generation Cloud Solution Stratas QMS

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today